title: [Do results of the recent clinical trials change the place of valproate in treatment of epilepsy?].
abstract: Valproate is one of the most extensively used antiepileptic drugs with a broad spectrum of efficacy and a relatively good tolerance. Results of two recently performed clinical trials (SANAD, VIP-e) indicate that valproate should remain first-line treatment in most patients with generalized seizures, and for its high efficacy valproate should be also considered as first-line therapy in patients with focal onset seizures.
authors.affiliation: Katedra i Klinika Neurologii, Uniwersytet Jagielloński Collegium Medicum, Kraków. magdalenabosak@wp.pl
authors.forename: Magdalena
authors.initials: M
authors.lastname: Bosak
mesh_terms: D000927:Anticonvulsants / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004827:Epilepsy / Q000188:drug therapy*; D006801:Humans; D012640:Seizures / Q000188:drug therapy; D014635:Valproic Acid / Q000627:therapeutic use*
chemical_list: D000927:Anticonvulsants; D014635:Valproic Acid